Future rheumatology-specific research should focus on the definition of new therapeutic targets, improving the understanding of existing therapies, engaging patients in their care and more, according to a recent assessment by the ACR’s Committee on Research…
The ACR Addresses the FDA about the Safe Adoption of Biosimilars in the U.S.; Plus Tofacitinib Approved for RA & Romosozumab May Reduce Fracture Risk
The ACR has continued its advocacy to ensure the safe adoption of biosimilars in the U.S., most recently addressing an FDA public hearing. Also, the FDA has approved tofacitinib for RA, and a clinical trial of romosozumab for patients with osteoporosis met its primary endpoint…
Routine Osteoporosis Screening in Men Proves Cost-Effective
NEW YORK (Reuters Health)—Routine osteoporosis screening in men is a good value and effective based on a cost-effectiveness model, researchers say. “Osteoporosis is not just a disease for women. Osteoporosis affects many men (approximately 2 million in the U.S.), with significant morbidity, mortality, and costs that are projected to rise with the aging of the…
Doctor Quality Ratings May Be Influenced By Setting
(Reuters Health)—Patients give the same doctors different ratings depending on where their visit took place, according to a small U.S. study. Although doctors might act differently in an emergency department compared with a calmer office setting, researchers say the results also suggest that ratings are not a completely reliable measure of the quality of care…
Europe Launches New Fast Approval Scheme for Promising Drugs
LONDON (Reuters)—European regulators launched a new scheme on Monday to speed the approval of promising new drugs that address unmet medical needs by offering enhanced support to medicine developers as they work on clinical trials. The European Medicines Agency‘s (EMA) initiative called PRIME, which stands for PRIority MEdicines, is the latest example of regulators on…
Do Bisphosphonates Increase Risk of Carpal Tunnel Syndrome?
In a large-scale study, researchers demonstrated that the use of bisphosphonates in postmenopausal women is associated with an increased risk of carpal tunnel syndrome, in addition to other known risks (e.g., incapacitating bone, joint and/or musculoskeletal pain, and osteonecrosis of the jaw)…
From the Expert: Insight into the Intersection of Cancer & Autoimmunity
Research by Dr. Anthony Rosen, MD, and colleagues found a link between cancer and scleroderma, suggesting the immune system may edit cancer cells. In an interview with The Rheumatologist, Dr. Rosen explores the meaning of this finding and its potential…
Patients Get Mixed Reactions from Docs over Mail-Ordered Genetic Tests
(Reuters Health)—Patients who order direct-to-consumer genetic tests report mixed experiences when they take the results to their doctors, a new study found. About a quarter of people who ordered direct-to-consumer genetic testing from such companies as 23andMe reported discussing the results with their primary care doctors. But nearly one in five were not at all…
Tofacitinib Shows Ongoing Action Against Plaque Psoriasis
NEW YORK (Reuters Health)—The oral Janus kinase inhibitor tofacitinib (Xeljanz, Pfizer) shows long-term efficacy against chronic plaque psoriasis, according to findings from two randomized studies and an extension trial. The outcome, Dr. Svitlana Tatulych told Reuters Health by email, “demonstrated that oral tofacitinib, at both the 10 mg and 5 mg twice-daily doses, provided sustained…
Titanium Dioxide Additives May Boost Intestinal Inflammation
NEW YORK (Reuters Health)—Murine and other studies suggest that titanium dioxide (TiO2) nanoparticles, widely used as food additives and in drug formulations, may be involved in intestinal inflammation, according to Swiss researchers. As Dr. Gerhard Rogler told Reuters Health by email, “It seems that titanium dioxide nanoparticles are not harmful for a healthy person with…
- « Previous Page
- 1
- …
- 517
- 518
- 519
- 520
- 521
- …
- 814
- Next Page »